|
Cytokinetics 8-K 2017
UNITED STATES FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Cytokinetics, Incorporated
Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 2.02 Results of Operations and Financial Condition.
On February 16, 2017, Cytokinetics, Incorporated issued a press release announcing its results for the fourth quarter ended December 31, 2016. A copy of the press release is being filed as Exhibit 99.1 to this Current Report and is hereby incorporated by reference into this item 2.02. Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Exhibit Index
|